Group 1 - The Hang Seng Index rose by 0.19%, gaining 48 points to close at 25,809 points, while the Hang Seng Tech Index increased by 0.58% [1] - The trading volume in the Hong Kong stock market reached 92.2 billion HKD in the morning session [1] - Robotics concept stocks led the gains, with several stocks rising over 3%, driven by reports of the Trump administration promoting the robotics industry [1] Group 2 - UBTECH (09880) rose over 3% after announcing a partnership with ZHOS Technology to deploy 10,000 humanoid robots over five years [2] - Hesai Technology (02525) increased by over 6% following the release of its self-developed RISC-V laser radar main control chip, Fermi C500 [2] - InnoCare Pharma (02577) saw a rise of over 4% after forming a strategic partnership with ON Semiconductor to advance the GaN ecosystem [2] - Dazhong Public Utilities (01635) surged over 6% ahead of the listing of Moole Thread, with its subsidiary Deep Venture Capital participating in the investment [2] - Global New Materials International (06616) rose over 5%, with its stock price doubling since the end of October, following an increase in holdings of Seven Color Pearl Coatings [2] - Gilead Sciences-B (01672) increased over 9% after repurchasing 1.3 million shares and announcing a buyback of up to 300 million HKD [2] - Kacos-B (01167) saw a mid-session rise of over 5% after its subsidiary received a 125 million HKD initial payment for a joint therapy featured in The Lancet [2] - Pacific Shipping (02343) rose over 4% as the BDI index reached a nearly two-year high, indicating a turning point for the dry bulk shipping industry [2] - Capital Market Holdings (00204) fell over 40%, with a cumulative decline of over 80% this week, following a significant transfer of shares [2]

Group 1 - The core viewpoint of the articles highlights significant stock movements in the Hong Kong and US markets, driven by company announcements and strategic partnerships [1][2][5][6][7]. Group 2 - Gilead Sciences-B (01672) saw a nearly 9% increase after announcing a share buyback plan, utilizing up to 300 million HKD for repurchases [1]. - OSL Group (00863) rose nearly 2% as it plans to offer compliant digital asset trading services in Europe by Q1 2026 [1]. - Gako Science-B (01167) increased over 5% following a 125 million RMB payment from Haisheng Capital, enhancing its cash reserves for oncology therapy development [1]. - Zhida Technology (02650) surged over 4%, reaching a new high, after signing a sales order exceeding 100 million RMB with Saudi Controls Ltd for a five-year collaboration [2]. - Capital界金控 (00204) fell over 40%, marking a historical low, with a cumulative decline exceeding 80% for the week [2]. - Semiconductor stocks performed well, with Huahong Semiconductor (01347) up 3.18%, Shanghai Fudan (01385) up 2.79%, and SMIC (00981) up 1.86% [2]. - Pacific Shipping (02343) rose nearly 5% as the Baltic Dry Index reached 2845 points, a 9.42% increase, marking the largest rise since October 2025 [3]. - Aoda Holdings (09929) resumed trading with a surge of over 200%, following a major share sale involving 1.5 billion shares at a price of 0.11 HKD per share [4]. - Robotics stocks saw significant gains, with Dechang Motor Holdings (00179) up 9.11% and Sanhua Intelligent Control (02050) up 9.06% [4]. - Ansem Semiconductor (ON.US) rose 11.01% after announcing a strategic partnership with Innosec to advance GaN technology applications [5]. - The Nasdaq Golden Dragon Index fell 1.38%, with notable declines in popular Chinese stocks like Xpeng Motors (XPEV.US) down 4.02% and Alibaba (BABA.US) down 1.89% [5]. - Microchip Technology (MCHP.US) increased by 12.17% after raising its revenue and earnings per share forecasts due to strong booking performance [6]. - Bitcoin-related stocks saw gains, with Iren Ltd (IREN.US) up 6.91% and Coinbase (COIN.US) up 5.19% [6]. - The robotics sector in the US experienced a boost, with Richtech Robotics (RR.US) up 18.54% and iRobot (IRBT.US) up 73.85% amid government support for the industry [7].

Core Viewpoint - The stock price of 加科思-B (01167) increased by 6.17% to HKD 8.09, with a trading volume of HKD 17.6587 million, following the announcement of a capital increase and equity transfer agreement [1][5] Group 1: Financial Developments - 加科思's subsidiary, 北京加科思, received a first payment of RMB 125 million from 海松资本 as part of the capital increase and equity transfer agreement, enhancing the group's cash reserves [1][5] - The influx of funds is expected to support the development of innovative cancer therapy pipelines [1][5] Group 2: Clinical Research Achievements - 加科思 announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, glecirasib, in combination with SHP2 inhibitor JAB-3312, were published in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1][5] - This publication marks the first systematic clinical data on the combination of KRAS G12C and SHP2 dual oral small molecule therapy to be featured in such a high-profile journal [1][5]

Core Viewpoint - The stock of 加科思-B (01167) has seen a significant increase, attributed to positive developments in its financial and clinical research activities [1] Financial Developments - 加科思's subsidiary, 北京加科思, has received an initial payment of RMB 125 million from 海松资本, enhancing the group's cash reserves [1] - The receipt of this payment is expected to support the advancement of the group's innovative oncology therapy pipeline [1] Clinical Research Achievements - 加科思 announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, glecirasib, in combination with SHP2 inhibitor JAB-3312, have been published in the prestigious medical journal, The Lancet Respiratory Medicine [1] - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has appeared in such a high-impact journal [1]

Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, with a current price of HKD 8.04 and a trading volume of HKD 8.1525 million. The company has received a substantial payment that enhances its cash reserves and supports its ongoing research in innovative cancer therapies [1]. Group 1 - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, which bolsters the group's cash reserves [1]. - The receipt of this payment is expected to facilitate the advancement of the company's pipeline for innovative cancer therapies [1]. Group 2 - Gossamer Bio announced the publication of clinical I/IIa study results for its self-developed KRAS G12C inhibitor, Glecirasib, in combination with SHP2 inhibitor JAB-3312 (Sitneprotafib) in the prestigious medical journal, The Lancet Respiratory Medicine, which has an impact factor of 32.8 [1]. - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has been featured in such a reputable journal [1].

Core Viewpoint - The stock of Gossamer Bio, Inc. (01167) has seen a significant increase, rising over 6% during trading, attributed to positive developments in the company's financial and clinical research activities [1] Financial Developments - Gossamer Bio's subsidiary, Beijing Gossamer, has received an initial payment of RMB 125 million from Haisong Capital, enhancing the group's cash reserves [1] - The receipt of this payment is expected to support the advancement of the company's innovative oncology therapy pipeline [1] Clinical Research Achievements - Gossamer Bio announced that the clinical I/IIa study results of its self-developed KRAS G12C inhibitor, Glecirasib, in combination with the SHP2 inhibitor, JAB-3312, have been published in the prestigious medical journal, The Lancet Respiratory Medicine [1] - This publication marks the first time systematic clinical data on the combination of KRAS G12C and SHP2 oral small molecule therapies has appeared in such a high-impact journal [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 加科思藥業集團有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01167 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 1,000,000,000 | USD | | 0.0001 | USD | | 100,000 | 本月底法定 ...

本文源自：财华网 【财华社讯】加科思(01167.HK)公布，有关北京加科思、加科瑞康、海松资本及一名产业合作方订立的 增资协议及股权转让协议。公司附属公司北京加科思，就其订立的增资协议及股权转让协议，已收到海 松资本支付的人民币1.25亿元的首付款。该首付款的到账，进一步充盈了集团的现金储备，也将为集团 后续创新肿瘤疗法管线研发的推进提供助力。 ...

Core Viewpoint - The announcement by 加科思-B (01167) regarding the capital increase and equity transfer agreement signifies a strategic move to enhance cash reserves and support the development of innovative cancer therapies [1] Group 1: Financial Transactions - The company’s subsidiary, 北京加科思, has received an initial payment of RMB 125 million from 海松资本 as part of the capital increase agreement [1] - This initial payment is expected to bolster the group's cash reserves, providing financial support for future research and development initiatives [1] Group 2: Strategic Implications - The agreements with 海松资本 and other partners are aimed at advancing the company's pipeline for innovative cancer therapies [1] - The successful execution of these agreements reflects the company's commitment to enhancing its operational capabilities and expanding its therapeutic offerings in the oncology sector [1]

格隆汇12月2日丨加科思-B(01167.HK)公布，有关北京加科思、加科瑞康、海松资本及一名产业合作方 订立的增资协议及股权转让协议。公司附属公司北京加科思(公司间接非全资附属公司)，就其订立的增 资协议及股权转让协议，已收到海松资本支付的人民币1.25亿元的首付款。该首付款的到账，进一步充 盈了集团的现金储备，也将为集团后续创新肿瘤疗法管线研发的推进提供助力。 ...